JP2017508805A5 - - Google Patents

Info

Publication number

JP2017508805A5

JP2017508805A5 JP2016575627A JP2016575627A JP2017508805A5 JP 2017508805 A5 JP2017508805 A5 JP 2017508805A5 JP 2016575627 A JP2016575627 A JP 2016575627A JP 2016575627 A JP2016575627 A JP 2016575627A JP 2017508805 A5 JP2017508805 A5 JP 2017508805A5

Authority

JP

Japan

Prior art keywords

compound

item

solid dispersion

solvents

pharmaceutical composition

Prior art date

2015-03-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims description 58
• 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims description 30
• 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims description 30
• 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims description 30
• 229940125904 compound 1 Drugs 0.000 claims description 29
• 239000007962 solid dispersion Substances 0.000 claims description 23
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 16
• 108700028369 Alleles Proteins 0.000 claims description 15
• 239000008194 pharmaceutical composition Substances 0.000 claims description 14
• 239000013078 crystal Substances 0.000 claims description 11
• AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 8
• 229920000642 polymer Polymers 0.000 claims description 8
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
• 239000000203 mixture Substances 0.000 claims description 3
• 239000002904 solvent Substances 0.000 claims 8
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
• 238000001694 spray drying Methods 0.000 claims 4
• WIJZXSAJMHAVGX-DHLKQENFSA-N ivosidenib Chemical compound FC1=CN=CC(N([C@H](C(=O)NC2CC(F)(F)C2)C=2C(=CC=CC=2)Cl)C(=O)[C@H]2N(C(=O)CC2)C=2N=CC=C(C=2)C#N)=C1 WIJZXSAJMHAVGX-DHLKQENFSA-N 0.000 claims 2
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 2
• IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims 1
• ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
• 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims 1
• 230000035772 mutation Effects 0.000 description 37
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 20
• 102200069690 rs121913500 Human genes 0.000 description 19
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 18
• 230000009033 hematopoietic malignancy Effects 0.000 description 18
• 102200069708 rs121913499 Human genes 0.000 description 13
• 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 10
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 10
• HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 9
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• 230000001419 dependent effect Effects 0.000 description 8
• KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 7
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 6
• 102200069689 rs121913500 Human genes 0.000 description 6
• 206010025323 Lymphomas Diseases 0.000 description 5
• 201000010099 disease Diseases 0.000 description 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
• 206010042971 T-cell lymphoma Diseases 0.000 description 4
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 3
• 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 3
• 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 3
• 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 3
• 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 3
• 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 description 3
• 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 3
• 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 3
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
• 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 102100022678 Nucleophosmin Human genes 0.000 description 3
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
• 208000037844 advanced solid tumor Diseases 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 238000004611 spectroscopical analysis Methods 0.000 description 3
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 150000001875 compounds Chemical class 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
• 229940126062 Compound A Drugs 0.000 description 1
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1